Amyloidosis trials in South Korea
10 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Gwangju, Seoul
- Age
- 18 years to 90 years
- People
- 1,200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - Phase 3Enrolling by invitationA Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Seoul
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06679946 - Phase 3Taking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Busan, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 1,280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - Phase 3Taking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Incheon, Seoul
- Age
- 18 years to 85 years
- People
- 1,750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - Phase 3Taking peopleTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Seoul
- Age
- 18 years to 85 years
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - Phase 3Not yet taking people in South KoreaAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Busan, Seoul
- People
- 1,180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - Phase 1/2Taking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Seoul
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - Phase 3Taking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Seoul
- Age
- 18 years to 75 years
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - No phaseNot yet taking people in South KoreaEarly Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
- Where
- Seoul
- Age
- 19 years and over
- People
- 500
- Run by
- Samsung Medical Center
See details and how to joinNCT07567508 - No phaseTaking peoplePhysiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
- Where
- Seoul
- Age
- 18 years to 85 years
- People
- 30
- Run by
- Samsung Medical Center
See details and how to joinNCT02798705